The Contribution of Drugs and Helicobacter pylori to Gastric Mucosa Changes in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Table 4

Endoscopic gastric mucosal changes in the examined patients and detection rates of H. pylori.

Gastric mucosa status at endoscopy	PAPS		SLE+APS		SLE		All patients
	n = 20		n = 26		n = 39		n = 85
	H. pylori (+)	H. pylori (-)	H. pylori (+)	H. pylori (-)	H. pylori (+)	H. pylori (-)	H. pylori (+)	H. pylori (-)
	n = 14 (70.0%)	n = 6 (30.0%)	n = 21 (80.8%)	n = 5 (19.2%)	n = 31 (79.5%)	n = 8 (20.5%)	n = 66 (77.6%)	n = 19 (22.4%)
All patients with gastric mucosal changes, n (%)	12 (85.7)	6 (100)	21 (100)	5 (100)	28 (90.3)	5 (62.5)	61 (92.4)	16 (84.2)
Antral gastritis, n (%)	11 (78.6)	6 (100)	20 (95.2)	5 (100)	23 (74.2)	5 (62.5)	54 (81.8)	16 (84.2)
Pangastritis, n (%)	1 (7.1)	0	1 (4.8)	0	5 (16.6)	0	7 (10.6)	0
Gastric mucosal erosion, n (%)	5 (35.7)	0	7 (33.3)	3 (60.0)	5 (16.6)	1 (12.5)	17 (25.6)	4 (21,2)
Gastric mucosal hemorrhage, n (%)	1 (7.1)	1 (16.7)	2 (9.5)	1 (20.0)	2 (6.4)	0	5 (7.6)	2 (10.5)
Intact gastric mucosa, n (%)	2 (14.3)	0	0	0	3 (10.0)	3 (33.3)	5 (7.8)	3 (14.3)

Note: H. pylori was detected by PCR.